Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, Germany.
GESIS-Leibniz-Institute for the Social Sciences, Mannheim, Germany.
Acta Otorhinolaryngol Ital. 2023 Dec;43(6):390-399. doi: 10.14639/0392-100X-N2279. Epub 2023 Oct 10.
The Sino-Nasal Outcome Test 22 (SNOT-22) is a validated patient-reported outcome instrument to evaluate the health-related quality of life (HRQoL) in patients with chronic rhinosinusitis (CRS). There are no published normative SNOT-22 scores, limiting its interpretation.
Symptom scores from 1,000 SNOT-22 questionnaires were analysed by principal component analysis (PCA) and exploratory factor analyses. Data were derived from a survey with 1,000 healthy Europeans (reference cohort) who were recruited using the Respondi panel for market and social science research. This subsample was quoted to the population distribution of the German Microcensus and selected from a non-probability panel.
The overall normative SNOT-22 score can be detected to be 20.2 ± 19.44. Male (18.49 ± 19.15) and older (> 50 years old; 18.3 ± 17.49) participants had overall lower SNOT-22 mean results than females (21.8 ± 19.6) and younger (21.4 ± 20.55) participants, indicating higher levels of satisfaction. PCA proposed two SNOT-22 domains ("physiological well-being" and "psychological well-being"), which explained 65% of the variance.
These are the first published (German) normative scores for the SNOT-22 and provide a clinical reference point for the interpretation of data.
SNOT-22 是一种经过验证的患者报告结局工具，用于评估慢性鼻-鼻窦炎（CRS）患者的健康相关生活质量（HRQoL）。目前尚无发表的 SNOT-22 规范评分，限制了其解读。
通过主成分分析（PCA）和探索性因子分析对 1000 份 SNOT-22 问卷的症状评分进行分析。数据来自一项针对 1000 名健康欧洲人的调查，该调查使用 Respondi 小组进行市场和社会科学研究招募。该子样本引用了德国微型人口普查的人口分布，并从非概率小组中选择。
总体规范 SNOT-22 评分为 20.2 ± 19.44。男性（18.49 ± 19.15）和年龄较大（>50 岁；18.3 ± 17.49）的参与者的总体 SNOT-22 平均结果低于女性（21.8 ± 19.6）和年龄较小（21.4 ± 20.55）的参与者，表明满意度更高。PCA 提出了两个 SNOT-22 领域（“生理幸福感”和“心理幸福感”），解释了 65%的方差。
这是首次发表的（德国）SNOT-22 规范评分，为数据解释提供了临床参考点。
